E3 PreliminaryPreliminaryPEM unclearReview-NarrativePeer-reviewedMachine draft
The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders.
Dobryakova, Ekaterina, Genova, Helen M, DeLuca, John et al. · Frontiers in neurology · 2015 · DOI
Quick Summary
This review examines why people with MS experience severe fatigue by looking at brain imaging studies and medication trials. The researchers propose that fatigue may result from a chemical imbalance in the brain involving dopamine, a messenger that helps different brain regions communicate with each other. They found that medications that boost dopamine can help reduce fatigue in various conditions, suggesting this chemical might be key to understanding fatigue.
Why It Matters
Understanding dopamine's role in fatigue could lead to new treatments for ME/CFS patients, many of whom experience debilitating fatigue similar to MS. This hypothesis provides a testable biological mechanism that bridges neuroimaging findings with pharmacological responses, potentially opening pathways for targeted interventions. The inclusion of chronic fatigue syndrome in the dopamine discussion directly connects this MS research to ME/CFS populations.
Observed Findings
- Structural and functional neuroimaging studies show abnormalities in frontal and striatal brain regions that are heavily dopamine-innervated in fatigued MS patients.
- Dopaminergic psychostimulant medications reduce fatigue in MS, traumatic brain injury, chronic fatigue syndrome, and cancer patients.
- Neuroimaging evidence suggests disrupted communication between the striatum and prefrontal cortex in fatigued individuals.
Inferred Conclusions
- Dopamine imbalance, particularly affecting striatal-prefrontal cortex communication, may be a unifying mechanism underlying fatigue in MS and other neurological conditions.
- Dopaminergic medication response in multiple disease populations suggests dopamine dysfunction could be a common final pathway in fatigue pathophysiology.
- Structural and functional brain abnormalities in dopamine-rich regions provide neurobiological support for testing the dopamine imbalance hypothesis in future studies.
Remaining Questions
- Does dopamine dysfunction directly cause fatigue in ME/CFS, or is it a secondary consequence of other pathological processes?
- How do specific patterns of striatal-prefrontal cortex dysfunction differ between ME/CFS and other fatigue-associated conditions?
- Can dopamine-targeting interventions be effective and tolerable in ME/CFS populations, and what biomarkers might predict treatment response?
What This Study Does Not Prove
This review does not prove that dopamine imbalance causes fatigue in ME/CFS—it primarily synthesizes existing MS literature and extrapolates to other conditions. The mechanism may differ between MS and ME/CFS given their distinct etiologies. Showing that dopamine-enhancing drugs help fatigue does not definitively establish dopamine deficiency as the primary cause, as these medications have multiple neurobiological effects.
Tags
Symptom:Fatigue
Biomarker:Neuroimaging
Method Flag:Exploratory Only
Metadata
- DOI
- 10.3389/fneur.2015.00052
- PMID
- 25814977
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →